section name header

Pronunciation

eye-sa-vue-kon-a-ZOE-nee-um

Classifications

Therapeutic Classification: antifungals

Pharmacologic Classification: azoles

Indications

REMS


Action

  • A prodrug that is converted (rapidly hydrolyzed) to isavuconazole. Inhibits the synthesis of ergosterol, a key component of fungal cell walls.
Therapeutic effects:
  • Resolution of invasive fungal infections.

Spectrum:

Pharmacokinetics

Absorption: Prodrug is rapidly converted to isavuconazole, the active component. 98% absorbed following oral administration. IV administration results in complete bioavailability.

Distribution: Extensively distributed.

Protein Binding: >99%

Metabolism/Excretion: Extensively metabolized by liver by the CYP3A4 and CYP3A5 isoenzymes; inactive metabolites are mostly renally eliminated. <1% excreted unchanged in urine.

Half-Life: 130 hr

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hrunknown
IVunknownend of infusionunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, chest pain, hypotension

Derm: pruritus, rash, STEVENS-JOHNSON SYNDROME (SJS)

F and E: hypokalemia, hypomagnesemia

GI: liver enzymes, constipation, diarrhea, nausea, vomiting, appetite, dyspepsia

GU: renal failure

Local: injection site reactions

MS: back pain

Neuro: fatigue, headache, insomnia, anxiety, delirium

Resp: cough, dyspnea, respiratory failure

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), infusion-related reactions

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Cresemba